Measuring herpes zoster, zoster-associated pain, post-herpetic neuralgia-associated loss of quality of life, and healthcare utilization and costs in Thailand

Int J Dermatol. 2011 Apr;50(4):428-35. doi: 10.1111/j.1365-4632.2010.04715.x.

Abstract

Objectives: This study aimed to measure the herpes zoster-associated burden of illness, healthcare utilization, and costs among Thai patients.

Methods: This prospective cohort study of 180 patients aged ≥ 50 years and healthy, or ≥ 20 years and immunosuppressed, with zoster rash, was conducted in Bangkok and its environs, Thailand, during 2007-2008. Each patient was followed for six months for zoster-associated rash, pain, quality of life (QoL), and healthcare utilization and costs.

Results: A total of 180 subjects were enrolled in the study. Their mean ± standard deviation (SD) age was 58.9 ± 13.8 years. Of the 180 patients enrolled, 138 (76.7%), 34 (18.9%) and eight (4.4%) patients were elderly, HIV-infected, and receiving immunosuppressive agents, respectively; 35 (19.4%) had post-herpetic neuralgia (PHN), and 13 (7.2%) had zoster ophthalmicus. The severity of zoster pain was moderately highly correlated with activities of daily living (ADL), at 0.68 ≤ ρ ≤ 0.76. Most patients required only one or two outpatient visits. The mean ± SD total of direct healthcare costs was 3083.4 ± 5047.0 Thai baht or ∼ 1.1% of annual income per capita.

Conclusions: Herpes zoster contributes a significant burden of illness to both patients and the wider community.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Ambulatory Care / economics
  • Ambulatory Care / statistics & numerical data*
  • Cohort Studies
  • Female
  • Health Expenditures / statistics & numerical data*
  • Herpes Zoster / drug therapy
  • Herpes Zoster / economics
  • Herpes Zoster / epidemiology*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Middle Aged
  • Neuralgia, Postherpetic / drug therapy
  • Neuralgia, Postherpetic / economics
  • Neuralgia, Postherpetic / epidemiology*
  • Niacinamide / analogs & derivatives
  • Piperazines
  • Prospective Studies
  • Quality of Life*
  • Sick Leave / statistics & numerical data
  • Socioeconomic Factors
  • Surveys and Questionnaires
  • Thailand / epidemiology

Substances

  • AD 101
  • Immunosuppressive Agents
  • Piperazines
  • Niacinamide